Vivos Therapeutics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K, dated September 25, 2023, reports on the results of Vivos Therapeutics, Inc.'s 2023 Annual Meeting of Stockholders held on September 22, 2023. The company is an emerging growth company incorporated in Delaware with its principal executive offices in Littleton, Colorado. As of the August 11, 2023 record date, there were 29,928,786 shares of common stock outstanding entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder actions. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Approximately 18,568,640 shares were present or represented by proxy, constituting a quorum. Stockholders approved four key proposals:
- Proposal 1 (Stock Plan Amendment): Approved an amendment to the 2019 Stock Option and Stock Issuance Plan to increase authorized shares by 2,000,000, bringing the total to 4,366,667 shares. Voting results showed 6,038,248 shares for, 5,368,547 against, and 104,986 abstaining.
- Proposal 2 (Election of Directors): Elected six directors for one-year terms: Dr. Ralph Green, Anja Krammer, Mark Lindsay, Leonard Sokolow, Dr. Matthew Thompson, and R. Kirk Huntsman. All nominees received majority support, though voting was split for several candidates.
- Proposal 3 (Auditor Ratification): Ratified the appointment of Moss Adams LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. Results: 14,103,105 for, 4,180,361 against, and 285,174 abstaining.
- Proposal 4 (Reverse Stock Split): Approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between one-for-ten and one-for-thirty. The specific ratio is to be determined at the sole discretion of the Board of Directors. Results: 12,728,805 for, 5,697,904 against, and 141,930 abstaining.
Guidance, Outlook, and Risks
The filing does not provide management commentary on financial guidance, future outlook, or specific risk factors beyond the corporate actions taken. The approval of the reverse stock split indicates a strategic move to adjust the share structure, with the exact implementation details pending Board discretion.
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio once determined by the Board of Directors, as the filing only authorizes a range (1:10 to 1:30).
- Monitor the impact of the increased share authorization (2,000,000 additional shares) on future dilution.
- Review the significant number of shares voted against the stock plan amendment and reverse split to gauge shareholder sentiment.
- Confirm the effective date of the reverse stock split and any subsequent changes to the trading symbol or price on NASDAQ.